Earn 225 points upon purchasing this product.
$45.00
An analog called tesamorelin stimulates growth hormone release, raising IGF-1 levels in both males and females by an average of 181 micrograms per liter. With a potency similar to that of GHRH, this growth hormone can bind to and activate GHRH receptors.
Availability: In Stock
Tesmorelin is used to reduce excess abdominal fat in HIV-positive individuals who have altered body fat distribution. This adverse effect, which is characterized by a decrease in fat in the limbs and an increase in fat accumulation in the abdominal and upper back areas, can be brought on by some HIV medications. The way tesamorelin works is by encouraging the body to make more growth hormone.
An analog called tesamorelin stimulates growth hormone release, raising IGF-1 levels in both males and females by an average of 181 micrograms per liter. With a potency similar to that of GHRH, this growth hormone can bind to and activate GHRH receptors.
This growth hormone also hosts many benefits which include:
It has been demonstrated that tesamorelin reduces c-reactive protein (CRP), visceral adipose tissue (VAT), and carotid intima-media thickness (cIMT). However, there is no evidence that this growth hormone has a substantial impact on other pituitary hormones or other relevant bodily processes.
Additionally, patients with mild cognitive impairment who are at an increased risk of developing Alzheimer’s disease can benefit from tesamorelin by improving their cognitive function.
For its dosage, ensure to reconstitute each vial with 3 m: and inject 0.5 mL subcutaneously before bed 6 out of 7 nights 90 minutes after your last food intake. One vial should be reconstituted at a time.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using tesamorelin and call your doctor at once if you have a serious side effect such as:
Less serious side effects may include:
Reviews
There are no reviews yet.